The BioFire® FilmArray® Blood Culture Identification (BCID) Panel

Early identification and treatment of sepsis are essential to combat one of the leading causes of hospital patient deaths.1 The BioFire BCID Panel rapidly identifies the most common causes of bloodstream infection, reducing time to effective therapy, and potentially improving patient survival.2,3

27 TARGETS IN ONE TEST

The BioFire BCID Panel tests for a comprehensive set of 24 Gram-positive, Gram-negative and yeast pathogens and 3 antibiotic resistance genes associated with bloodstream infections. The BioFire BCID Panel detects and identifies the most common causes of bloodstream infections. Quickly identifying the cause of sepsis may help clinicians more rapidly and appropriately manage septic patient therapy.

GET PRICING

 

THE BIOFIRE BCID PANEL MENU

Overall 98% Sensitivity and 99.9% Specificity4
Sample Type: Positive Blood Culture

 

GRAM-POSITIVE BACTERIA:

● Enterococcus
● Listeria monocytogenes
● Staphylococcus
● Staphylococcus aureus
● Streptococcus
● Streptococcus agalactiae
● Streptococcus pneumoniae
● Streptococcus pyogenes

 

ANTIMICROBIAL RESISTANCE GENES:

● mecA – methicillin resistance
● vanA/B –
vancomycin resistance
● KPC –
carbapenem resistance

 

YEAST:
 
● Candida albicans
● Candida glabrata
● Candida krusei
● Candida parapsilosis
● Candida tropicalis

 
 
 
 
 
 
 

GRAM-NEGATIVE BACTERIA:

● Acinetobacter baumannii
● Haemophilus influenzae
● Neisseria meningitidis
● Pseudomonas aeruginosa
● Enterobacteriaceae
● Enterobacter cloacae
complex
● Escherichia coli
● Klebsiella oxytoca
● Klebsiella pneumoniae
● Proteus
● Serratia marcescens

 

Proven Effect of Antimicrobial Stewardship and the BioFire BCID Panel

Antimicrobial stewardship programs (ASP) optimize antimicrobial use to achieve the best clinical outcomes. The BioFire BCID Panel rapid pathogen identification, in combination with locally-derived treatment guidelines set by an ASP, can result in appropriate antimicrobial interventions.5

At Mayo Clinic, BioFire BCID Panel results reported with templated comments improved antimicrobial escalation, reduced treatment of contaminants, and decreased the use of broad-spectrum antimicrobials; addition of antimicrobial stewardship enhanced antimicrobial de-escalation.6

Adapted from Banerjee R, et al. Clinical Infectious Diseases 2015;61(7):1

Change in Patient Management

At the Children’s Hospital of Colorado, rapid BioFire BCID Panel results along with real-time antimicrobial stewardship support have been associated with improved patient treatment outcomes and high satisfaction ratings by providers. Median time to optimal therapy was reduced by 33.5 hours.7

Data derived from a provider survey.
Adapted from Messacar K, et al. Journal of the Pediatric Infectious Diseases Society; Advance Access published August 19, 2016.

Hospital Savings

Faster results from the BioFire BCID Panel allow clinicians to put patients on optimal antimicrobial therapy sooner, which in turn leads to better clinical and economic outcomes. Cost savings from ICU and pharmacy are sufficient to cover capital expenditure and reagent costs. Also, BioFire BCID Panel identification of coagulase negative staphylococci contaminants has previously resulted in shorter post-culture length of stay and saved roughly $30,000 per 100 patients tested.8

** Outcomes from patients with blood cultures growing gram-positive cocci and Candida.

“Adding the BCID to our ASP intervention was clearly beneficial, as time to effective therapy and time to first antimicrobial de-escalation occurred more rapidly, and utilization of narrow-spectrum therapies significantly increased, with no harmful effects on patient care.”2

– Medical University of South Carolina
Charleston, SC

Webinars

Publications and Posters

Supporting Documents

Other Available BioFire® Panels

References:

 

  1. Sepsis Alliance: Sepsis Fact Sheet 2016. [cited 2017 Aug 30]; [2 pages]. Available from: http://www.sepsis.org/downloads/2016_sepsis_facts_media.pdf
  2. MacVane SH, Nolte FS. Benefits of Adding a Rapid PCR-Based Blood Culture Identification Panel to an Established Antimicrobial Stewardship Program. J Clin Microbiol 2016; 54:2476-2484.
  3. Tristan T. Timbrook, Jacob B. Morton, Kevin W. McConeghy, Aisling R. Caffrey, Eleftherios Mylonakis, Kerry L. LaPlante; The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis, Clinical Infectious Diseases, Volume 64, Issue 1, 1 January 2017, Pages 15–23.
  4. Aggregated Prospective Performance from the FilmArray® Blood Culture Identification Panel Clinical Trial. Data on File, BioFire Diagnostics.
  5. Southern TR, VanSchooneveld TC, Bannister DL, Brown TL, Crismon AS, Buss SN, Iwen PC, Fey PD. Implementation and performance of the BioFire FilmArray® Blood Culture Identification Panel with antimicrobial treatment recommendations for bloodstream infections at a Midwestern academic tertiary hospital. Diagn Microbiol Infect Dis
    2015;81(2):96–101.
  6. Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND, Mandrekar JN, Patel R. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis 2015;61:1071-80.
  7. Kevin Messacar, Amanda L. Hurst, Jason Child, Kristen Campbell, Claire Palmer, Stacey Hamilton, Elaine Dowell, Christine C. Robinson, Sarah K. Parker, Samuel R. Dominguez. Clinical Impact and Provider Acceptability of Real-Time Antimicrobial Stewardship Decision Support for Rapid Diagnostics in Children With Positive Blood Culture Results. J Ped Infect Dis Soc 2016; piw047.
  8. Pardo J, Klinker KP, Borgert SJ, Butler BM, Giglio PG, Rand KH. Clinical and Economic Impact of Antimicrobial Stewardship Interventions With the FilmArray® Blood Culture Identification Panel. Diagn Microbiol Infect Dis 2016;84(2):159–164